These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 29289479)

  • 21. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium.
    Ditters IAM; Huidekoper HH; Kruijshaar ME; Rizopoulos D; Hahn A; Mongini TE; Labarthe F; Tardieu M; Chabrol B; Brassier A; Parini R; Parenti G; van der Beek NAME; van der Ploeg AT; van den Hout JMP;
    Lancet Child Adolesc Health; 2022 Jan; 6(1):28-37. PubMed ID: 34822769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme®) in 12 patients with advanced late-onset Pompe disease.
    Papadopoulos C; Orlikowski D; Prigent H; Lacour A; Tard C; Furby A; Praline J; Solé G; Hogrel JY; De Antonio M; Semplicini C; Deibener-Kaminsky J; Kaminsky P; Eymard B; Taouagh N; Perniconi B; Hamroun D; Laforêt P;
    Mol Genet Metab; 2017 Sep; 122(1-2):80-85. PubMed ID: 28648663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy.
    Parini R; De Lorenzo P; Dardis A; Burlina A; Cassio A; Cavarzere P; Concolino D; Della Casa R; Deodato F; Donati MA; Fiumara A; Gasperini S; Menni F; Pagliardini V; Sacchini M; Spada M; Taurisano R; Valsecchi MG; Di Rocco M; Bembi B
    Orphanet J Rare Dis; 2018 Feb; 13(1):32. PubMed ID: 29422078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease.
    Kanters TA; van der Ploeg AT; Kruijshaar ME; Rizopoulos D; Redekop WK; Rutten-van Mӧlken MPMH; Hakkaart-van Roijen L
    Orphanet J Rare Dis; 2017 Dec; 12(1):179. PubMed ID: 29237491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start.
    Stockton DW; Kishnani P; van der Ploeg A; Llerena J; Boentert M; Roberts M; Byrne BJ; Araujo R; Maruti SS; Thibault N; Verhulst K; Berger KI
    J Neurol; 2020 Oct; 267(10):3038-3053. PubMed ID: 32524257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease.
    Kanters TA; Hoogenboom-Plug I; Rutten-Van Mölken MP; Redekop WK; van der Ploeg AT; Hakkaart L
    Orphanet J Rare Dis; 2014 May; 9():75. PubMed ID: 24884717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical insight meets scientific innovation to develop a next generation ERT for Pompe disease.
    Kishnani PS; Chien YH; Berger KI; Thibault N; Sparks S
    Mol Genet Metab; 2024; 143(1-2):108559. PubMed ID: 39154400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations.
    Case LE; Beckemeyer AA; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):69-79. PubMed ID: 22252989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review.
    Toscano A; Schoser B
    J Neurol; 2013 Apr; 260(4):951-9. PubMed ID: 22926164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune responses to alglucosidase in infantile Pompe disease: recommendations from an Italian pediatric expert panel.
    Gragnaniello V; Deodato F; Gasperini S; Donati MA; Canessa C; Fecarotta S; Pascarella A; Spadaro G; Concolino D; Burlina A; Parenti G; Strisciuglio P; Fiumara A; Casa RD
    Ital J Pediatr; 2022 Mar; 48(1):41. PubMed ID: 35248118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).
    Schoser B; Kishnani PS; Bratkovic D; Byrne BJ; Claeys KG; Díaz-Manera J; Laforêt P; Roberts M; Toscano A; van der Ploeg AT; Castelli J; Goldman M; Holdbrook F; Sitaraman Das S; Wasfi Y; Mozaffar T;
    J Neurol; 2024 May; 271(5):2810-2823. PubMed ID: 38418563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
    Kishnani PS; Beckemeyer AA
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for a patient presenting with a PRKAG2 mutation.
    Austin SL; Chiou A; Sun B; Case LE; Govendrageloo K; Hansen P; Kishnani PS
    Mol Genet Metab; 2017; 120(1-2):96-100. PubMed ID: 27692944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.
    Strothotte S; Strigl-Pill N; Grunert B; Kornblum C; Eger K; Wessig C; Deschauer M; Breunig F; Glocker FX; Vielhaber S; Brejova A; Hilz M; Reiners K; Müller-Felber W; Mengel E; Spranger M; Schoser B
    J Neurol; 2010 Jan; 257(1):91-7. PubMed ID: 19649685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe Registry.
    Semplicini C; De Antonio M; Taouagh N; Béhin A; Bouhour F; Echaniz-Laguna A; Magot A; Nadaj-Pakleza A; Orlikowski D; Sacconi S; Salort-Campana E; Solé G; Tard C; Zagnoli F; Hogrel JY; Hamroun D; Laforêt P;
    J Inherit Metab Dis; 2020 Nov; 43(6):1219-1231. PubMed ID: 32515844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management.
    Kishnani PS; Beckemeyer AA; Mendelsohn NJ
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):1-7. PubMed ID: 22253049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease.
    de Vries JM; Brugma JD; Ozkan L; Steegers EA; Reuser AJ; van Doorn PA; van der Ploeg AT
    Mol Genet Metab; 2011 Dec; 104(4):552-5. PubMed ID: 21967859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis.
    Hundsberger T; Rösler KM; Findling O
    J Neurol; 2014 Sep; 261(9):1684-90. PubMed ID: 24923245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa.
    Lipinski SE; Lipinski MJ; Burnette A; Platts-Mills TA; Wilson WG
    Mol Genet Metab; 2009 Nov; 98(3):319-21. PubMed ID: 19640753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
    Diaz-Manera J; Kishnani PS; Kushlaf H; Ladha S; Mozaffar T; Straub V; Toscano A; van der Ploeg AT; Berger KI; Clemens PR; Chien YH; Day JW; Illarioshkin S; Roberts M; Attarian S; Borges JL; Bouhour F; Choi YC; Erdem-Ozdamar S; Goker-Alpan O; Kostera-Pruszczyk A; Haack KA; Hug C; Huynh-Ba O; Johnson J; Thibault N; Zhou T; Dimachkie MM; Schoser B;
    Lancet Neurol; 2021 Dec; 20(12):1012-1026. PubMed ID: 34800399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.